TLL.BO · BSE
Trident Lifeline Limited
₹404.75
+9.81% (+₹36.15)
Prev. close
₹368.6
Volume
1,57,800
As of
22 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Trident Lifeline Limited
Trident Lifeline Limited, together with its subsidiaries, manufactures and markets finished doses in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally. The company offers various medicinal products, including pharmaceuticals, nutraceuticals, herbals, and injectables in the form of tablets, capsules, dry powders for oral suspension, oral liquids, ointments, liquid ointments, effervescent tablets, sachets, pastes, gels, solutions, suspensions, ice gels, syrups, and creams, as well as toothpaste and mouthwash. Its products target a range of therapeutic solutions, such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, dental cure, proton pump inhibitor, antiprotozoal, antihistamine, antihypertensive drugs, antiparasitic, antilipidemic drugs, multivitamins, multiminerals, and non-steroidal anti-inflammatory drugs. The company is also involved in the manufacturing of formulations under proprietary brands; contract manufacturing arrangements; manufacture, trade, and distribution of skin and hair cosmetic products; and medical devices. It exports its products. The company has a strategic alliance with National Institutes of Pharmaceutical Education and Research- Ahmedabad (NIPER-A) for the technology transfer of Vorinostat, a medication for Cutaneous T-Cell Lymphoma (CTCL). Trident Lifeline Limited was incorporated in 2014 and is based in Surat, India.
Details
Sector
Healthcare
Industry
Pharmaceutical Retailers
CEO
Mr. Hardik Jigishkumar Desai
Headquarters
Surat
Employees
46
Website
tridentlifeline.comExchange
View on BSE ↗Key stats
Market cap
₹440.74 Cr
P/E ratio (TTM)
20.6
EPS (TTM)
₹17.93
Beta (1Y · daily vs NIFTY 50)
-0.23
Beta (5Y · monthly vs NIFTY 50)
0.65
Shares float
40.26 L
EPS · quarter ended Jun 2026
₹4.27
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹31.69 Cr | ₹44.63 Cr | ₹86.97 Cr | ₹129.02 Cr | |
| EBITDA | ₹7.41 Cr | ₹10.27 Cr | ₹23.09 Cr | ₹37.38 Cr |
| ₹6.02 Cr | ₹6.34 Cr | ₹11.75 Cr | ₹19.32 Cr | |
| Diluted EPS | ₹6.23 | ₹5.17 | ₹10.22 | ₹16.32 |
Other expenses has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹62.57 Cr | ₹87.08 Cr | ₹156.01 Cr | ₹236.83 Cr | |
| ₹7.69 Cr | ₹18.41 Cr | ₹54.03 Cr | ₹72.99 Cr | |
| Stockholders' equity | ₹45.63 Cr | ₹52.90 Cr | ₹64.46 Cr | ₹100.40 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹-19.00 Cr | ₹2.23 Cr | ₹-3.99 Cr | ₹4.69 Cr | |
| Investing cash flow | — | ₹-9.69 Cr | ₹-20.36 Cr | ₹-13.82 Cr | ₹-36.61 Cr |
| — | ₹42.28 Cr | ₹11.01 Cr | ₹13.50 Cr | ₹33.68 Cr | |
| Capital expenditure | — | ₹-6.92 Cr | ₹-17.89 Cr | ₹-11.10 Cr | ₹-36.47 Cr |
| End cash position | — | ₹13.78 Cr | ₹6.65 Cr | ₹2.46 Cr | ₹4.22 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.49 L Cr | ₹9,410.5 | 84.7 | 14.85 | 15.3% | 0.00 | +12.3% | +51.8% |
| Torrent Pharmaceuticals Limited | ₹1.84 L Cr | ₹4,970 | 77.5 | 21.95 | 25.8% | 1.79 | +21.5% | +36.9% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹691.45 | 179.0 | 13.55 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,161 | 25.8 | 4.27 | 18.6% | 0.46 | +18.4% | +11.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,006.5 | 99.3 | 20.57 | 16.8% | 0.48 | +22.0% | +122.0% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Manipal Health Enterprises Limited | ₹99,047.90 Cr | ₹746.1 | 152.1 | 11.75 | 7.8% | 1.53 | +18.0% | — |
| Dr. Reddy's Laboratories Limited | ₹98,709.15 Cr | ₹1,198.3 | 29.8 | 2.62 | 11.4% | 0.21 | +3.2% | -9.3% |
| Trident Lifeline Limited | ₹380.23 Cr | ₹315.05 | 17.7 | 3.79 | 19.0% | 0.73 | +48.4% | +8.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Trident Lifeline Share Price Rises 10.38%: Valuation View
Trident Lifeline Ltd. shares rose 10.38% to Rs 301, reaching a market capitalization of Rs 328.94 crore. The stock's price action showed a clear change and increased investor attention, though no specific company catalyst was identified. Its P/E ratio is below the industry median, while ROE and ROCE are above.